“The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer”, FE, vol. 14, no. 3, pp. 131–146, Sep. 2013, doi: 10.7175/fe.v14i3.700.